Safety and Tolerability Study of EG-1962 in Aneurysmal Subarachnoid Hemorrhage

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

73

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

January 31, 2016

Study Completion Date

January 31, 2016

Conditions
Ruptured Cerebral AneurysmRuptured Berry Aneurysm
Interventions
DRUG

Nimodipine

Based upon Investigator Judgement

DRUG

Nimodipine Microparticles

Based upon Investigator Judgement

Trial Locations (23)

10029

Mount Sinai Medical Center, New York

10032

Columbia University, New York

10065

Lenox Hill Hospital, New York

16902

Charles University, Department of Neurosurgery, Prague

21201

University of Maryland Medical Cnter, Baltimore

27705

Duke University Medical Center, Durham

29425

Medical University of South Carolina (MUSC), Charleston

37232

Vanderbilt University, Nashville

44195

The Cleveland Clinic Foundation, Cleveland

45219

Mayfield Clinic Inc, Cincinnati

60612

Rush University Medical Center, Chicago

85013

Barrow Neurological Institute, Phoenix

87131

University of New Mexico, Albuquerque

97239

Oregon Health and Science University, Portland

90095-7436

Ronald Reagan UCLA Medical Center, Los Angeles

07601

Hackensack University Medical Center, Hackensack

07901

Overlook Medical Center, Summit

T2N 1N4

University of Calgary, Foothills Medical Centre, Calgary

T6G 2B7

University of Alberta Hospital, Edmonton

M5B 1W8

St. Michael's Hospital, Toronto

M5T 2S8

University Health Network - Toronto General Division, Toronto Western Hospital, Toronto

S7N 0W8

University of Saskatchewan, Royal University Hospital, Saskatoon

00260

Helsinki University Central Hospital, Helsinki

Sponsors
All Listed Sponsors
lead

Edge Therapeutics Inc

INDUSTRY